Shire completes ‘robust’ deal in $5.2 billion NPS Pharmaceuticals acquisition, says GlobalData Analyst
16 January 2015 | By GlobalData
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData...